Treatment considerations of lung involvement in rheumatologic disease

Respiration

Volumn 90, Issue 4, 2015, Pages 265-274

  Robles Perez, Alejandro ^a   Molina Molina, Maria ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Connective tissue disease; Interstitial lung disease; Rheumatologic disease; Treatment

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ASSOCIATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MULTICENTER STUDY (TOPIC); POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHRINKING LUNG SYNDROME; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; COMPLICATION; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME;

ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID; POLYMYOSITIS; RITUXIMAB; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME;

EID: 84946493780     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000441238     Document Type: Review

References (93)

1. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586
2. Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2008; 33: 882-896
3. Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666
4. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-3970
5. Nadashkevich O, Davis P, Fritzler M, et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-212
6. Nannini C, West CP, Erwin PJ, et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and metaanalysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10: R124
7. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegeners granulomatosis. Arthritis Rheum 1997; 40: 2187-2198
8. Kowal-Bielecka O, Landewé R, Avouac J, et al. EUSTAR Co-Authors: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR). Ann Rheum Dis 2009; 68: 620-628
9. Poormoghim H, Rezaei N, Sheidae Z, et al. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement - A retrospective study. Rheumatol Int 2014; 34: 1691-1699
10. Iudici M, Cuomo G, Vettori S, et al. Lowdose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and nonresponders. Semin Arthritis Rheum 2015; 44: 437-444
11. Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008; 35: 1064-1072
12. Paone C, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1 year with low dose of cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007; 25: 613-616
13. Tzouvelekis A, Galanopoulos N, Bouros E, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012; 2012: 143637
14. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640-646
15. Yilmaz N, Can M, Kocakaya D, et al. Twoyear experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. Int J Rheum Dis 2014; 17: 923-928
16. Walker KM, Pope J. Participating Members of the Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group: Treatment of systemic sclerosis complications: what to use when first-line treatment fails - A consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42: 42-55
17. Panopoulos ST, Bournia VK, Trakada G, et al. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 2013; 191: 483-489
18. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010; 49: 271-280
19. Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30(suppl 71): S17-S22
20. Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54
21. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74: 1188-1194
22. Bosello S, De Luca G, Rucco M, et al. Longterm efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015; 44: 428-436
23. Papiris SA, Kagouridis K, Papadaki G, Kolilekas L, Manali ED. Treating CTDs related fibrotic ILDs by immunosuppressants: facts and faults. Lung 2014; 192: 221-223
24. Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J 2015; 46: 512-520
25. Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, et al. EUSTAR (EULAR Scleroderma Trials and Research Group): Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013; 72: 1217-1220
26. McMahan ZH, Wigley FM. Novel investigational agents for the treatment of scleroderma. Expert Opin Investig Drugs 2014; 23: 183-198
27. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label randomized phase 2 trial. Lancet 2011; 378: 498-506
28. van Laar MJ, Farge D, Sont JK, et al. The ASTIS trial: autologous stem cell transplantation versus iv pulse cyclophosphamide in poor prognosis systemic sclerosis, first results. EULAR, Annual Congress of the European League against Rheumatism. Ann Rheum Dis 2012; 71(suppl 3): 51
29. Barnett AJ. Scleroderma (progressive systemic sclerosis): progress and course based on a personal series of 118 cases. Med J Aust 1978; 2: 129-134
30. Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114: 801-807
31. Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602
32. Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease. Arthritis Rheum 2011; 63: 3078-3085
33. Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs 2014; 74: 443-450
34. Song J-W, Lee H-K, Lee CK, et al. Clinical course and outcome of rheumatoid arthritisrelated usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 103-112
35. Ogawa D, Hashimoto H, Wada J, et al. Successful use of cyclosporine A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 1422-1424
36. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci 2002; 17: 270-273
37. Puttick MP, Klinkhoff AV, Chalmers A, et al. Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. J Rheumatol 1995; 22: 2163-2165
38. Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 2008; 168: 1718-1719
39. Braun-Moscovici Y, Butbul-Aviel Y, Guralnik L, et al. Rituximab: rescue therapy in lifethreatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int 2013; 33: 1495-1504
40. Braun MG, Wagener P. Regression of peripheral and pulmonary rheumatoid nodules under therapy with rituximab (in German). Z Rheumatol 2013; 72: 166-171
41. Matteson E. Rituximab in rheumatoid arthritis lung disease. NCT00588565. https://www. clinicaltrials.gov/ct2/show/study/NCT00578.565?term=NCT00578565&rank=1§=Xc ba9870156 (updated September 25, 2012
42. Lioté H, Lioté F, Séroussi B, et al. Rituximabinduced lung disease: a systematic literature review. Eur Respir J 2010; 35: 681-687
43. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-1400
44. Dass S, Atzeni F, Vital E, et al. Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. Ann Rheum Dis 2011; 70(suppl 3): 71
45. Becerra G, Cambridge M. Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement. Ann Rheum Dis 2013; 72(suppl 3): 450
46. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014; 43: 613-626
47. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185: 1147-1153
48. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1065-1068
49. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-784
50. Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis-a meta-analysis of randomized controlled trials. Arthritis Rheum 2014; 66: 803-812
51. Alarcon GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997; 127: 356-364
52. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54: 1435-1439
53. Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009; 48: 1065-1068
54. Sawada T, Inokuma S, Sato T, et al. Study Committee for Leflunomide-Induced Lung Injury, Japan College of Rheumatology: Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1069-1072
55. Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011; 17: 362-367
56. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41: 256-264
57. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010; 69: 1086-1091
58. Herrinton LJ, Harrold LR, Liu L, et al. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf 2013; 22: 394-402
59. Robles-Perez A, Rodriguez-Sanchon B, Dorca J, et al. Preclinical lung disease in early rheumatoid arthritis. Chron Respir Dis 2015, in press
60. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 15: 373-381
61. Kreider M, Highland K. Pulmonary involvement in Sjögren syndrome. Semin Respir Crit Care Med 2014; 35: 255-264
62. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130: 1489-1495
63. Cha SI, Fessler MB, Cool CD, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006; 28: 364-369
64. Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögrens syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996; 154: 794-799
65. Gottenberg JE, Cinquetti G, Larroche C, et al. Club Rhumatismes et Inflammations and the French Society of Rheumatology: Efficacy of rituximab in systemic manifestations of primary Sjögrens syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72: 1026-1031
66. Swartz MA, Vivino FB. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögrens syndrome with rituximab. J Clin Rheumatol 2011; 17: 454
67. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögrens syndrome. Ann Rheum Dis 2007; 66: 351-357
68. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277
69. Winslow WA, Ploss LN, Loitman B. Pleuritis in systemic lupus erythematosus: its importance as an early manifestation in diagnosis. Ann Intern Med 1958; 49: 70-88
70. Muangchan C, van Vollenhoven RF, Bernatsky SR, et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2015, Epub ahead of print
71. Colby TV. Pulmonary pathology in patients with systemic autoimmune diseases. Clin Chest Med 1998; 19: 587-612
72. Gutsche M, Rosen GD, Swigris JJ. Connective tissue disease-associated interstitial lung disease: a review. Curr Respir Care Rep 2012; 1: 224-232
73. Martínez-Martínez MU, Abud-Mendoza C. Recurrent diffuse alveolar haemorrhage in a patient with systemic lupus erythematosus: long-term benefit of rituximab. Lupus 2012; 21: 1124-1127
74. Al Rashidi A, Alajmi M, Hegazi MO. Mycophenolate mofetil as a maintenance therapy for lupus-related diffuse alveolar hemorrhage: a case report. Lupus 2011; 20: 1551-1553
75. Claridge S, Das P, Dorling A, et al. Plasmapheresis as a rescue therapy for systemic lupus erythematosus-associated diffuse alveolar haemorrhage. BMJ Case Rep 2011; 2011: bcr0220113893
76. Carmier D, Diot E, Diot P. Shrinking lung syndrome: recognition, pathophysiology and therapeutic strategy. Expert Rev Respir Med 2011; 5: 33-39
77. Calderaro DC, Ferreira GA. Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases. Rheumatol Int 2012; 32: 1391-1396
78. Carmier D, Marchand-Adam S, Diot P, et al. Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir 2010; 27: e66-e78
79. Peñacoba Toribio P, Córica Albani ME, Myos Pérez M, et al. Rituximab in the treatment of shrinking lung syndrome in systemic lupus erythematosus. Rheumatol Clin 2013; 10: 325-327
80. Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest 2010; 138: 1464-1474
81. Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245-250
82. Marie I, Hatron PY, Dominique S, et al. Shortterm and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63: 3439-3447
83. Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136: 1341-1347
84. Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32: 273-284
85. Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013; 65: 800-808
86. Lega JC, Reynaud Q, Belot A, et al. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 2015; 24: 216-238
87. Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 2015; 54: 39-44
88. Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 2013; 107: 890-896
89. Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48: 968-971
90. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013; 143: 814-824
91. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011; 30: 1393-1398
92. Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjögrens syndrome (openlabel proof of concept ASAP study). Ann Rheum Dis 2014; 73: 1393-1396
93. Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther 2008; 10(suppl 1): S5